Glycine Receptor Alpha1 IgG, Cell Binding Assay, Serum
Use
Evaluating patients with suspected autoimmune stiff-person spectrum disorders, including stiff-person syndrome, stiff-limb and stiff trunk syndromes, or progressive encephalomyelitis with rigidity and myoclonus (PERM), using serum specimens. These disorders are associated with exaggerated startle, stiffness, and spasms of the axis and/or limbs. The test is particularly useful for diagnosing patients who are seronegative for GAD65-IgG but may have antibodies against the GlyRa1 antigen.
Special Instructions
Not provided.
Limitations
Negative results do not exclude autoimmune stiff-person spectrum or cancer. The antibody is detected in 19% of patients who are GAD65-IgG seronegative. Disease-specific antibodies may be present in serum, CSF, or both. False negatives can occur if the antibody concentration is below the detection limit.
New York Approved
Methodology
Cell-based / Cytometry
Biomarkers
Glycine Receptor Alpha1
Protein
LOINC Codes
- 96496-5 - GlyRa-1 IgG Ser Ql CBA IFA
- 96496-5 - GlyRa-1 IgG Ser Ql CBA IFA
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
Not provided
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |